332 related articles for article (PubMed ID: 21204588)
41. Adherence to oral bisphosphonates and the risk of subtrochanteric and femoral shaft fractures among female medicare beneficiaries.
Wang Z; Ward MM; Chan L; Bhattacharyya T
Osteoporos Int; 2014 Aug; 25(8):2109-16. PubMed ID: 24846316
[TBL] [Abstract][Full Text] [Related]
42. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
[TBL] [Abstract][Full Text] [Related]
43. Cost and consequences of noncompliance to oral bisphosphonate treatment.
Eisenberg DF; Placzek H; Gu T; Krishna A; Tulsi BB
J Manag Care Spec Pharm; 2015 Jan; 21(1):56-65. PubMed ID: 25562773
[TBL] [Abstract][Full Text] [Related]
44. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia.
Darkow T; Henk HJ; Thomas SK; Feng W; Baladi JF; Goldberg GA; Hatfield A; Cortes J
Pharmacoeconomics; 2007; 25(6):481-96. PubMed ID: 17523753
[TBL] [Abstract][Full Text] [Related]
45. Epidemiology, treatment and costs of osteoporosis in Germany--the BoneEVA Study.
Häussler B; Gothe H; Göl D; Glaeske G; Pientka L; Felsenberg D
Osteoporos Int; 2007 Jan; 18(1):77-84. PubMed ID: 17048064
[TBL] [Abstract][Full Text] [Related]
46. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model.
Patrick AR; Schousboe JT; Losina E; Solomon DH
J Clin Endocrinol Metab; 2011 Sep; 96(9):2762-70. PubMed ID: 21733991
[TBL] [Abstract][Full Text] [Related]
47. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
[TBL] [Abstract][Full Text] [Related]
48. Medical costs and hospitalizations among patients with depression treated with adjunctive atypical antipsychotic therapy: an analysis of health insurance claims data.
Halpern R; Nadkarni A; Kalsekar I; Nguyen H; Song R; Baker RA; Nelson JC
Ann Pharmacother; 2013; 47(7-8):933-45. PubMed ID: 23715066
[TBL] [Abstract][Full Text] [Related]
49. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
Watts NB; Worley K; Solis A; Doyle J; Sheer R
J Manag Care Pharm; 2004; 10(2):142-51. PubMed ID: 15032563
[TBL] [Abstract][Full Text] [Related]
50. Physician perception of patient adherence compared to patient adherence of osteoporosis medications from pharmacy claims.
Copher R; Buzinec P; Zarotsky V; Kazis L; Iqbal SU; Macarios D
Curr Med Res Opin; 2010 Apr; 26(4):777-85. PubMed ID: 20095797
[TBL] [Abstract][Full Text] [Related]
51. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting.
Chastek B; Korrer S; Nagar SP; Albers F; Yancey S; Ortega H; Forshag M; Dalal AA
J Manag Care Spec Pharm; 2016 Jul; 22(7):848-61. PubMed ID: 27348285
[TBL] [Abstract][Full Text] [Related]
52. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
53. Teriparatide treatment patterns in osteoporosis and subsequent fracture events: a US claims analysis.
Bonafede MM; Shi N; Bower AG; Barron RL; Grauer A; Chandler DB
Osteoporos Int; 2015 Mar; 26(3):1203-12. PubMed ID: 25567774
[TBL] [Abstract][Full Text] [Related]
54. Adherence to antiretroviral therapy in managed care members in the United States: a retrospective claims analysis.
Cooke CE; Lee HY; Xing S
J Manag Care Pharm; 2014 Jan; 20(1):86-92. PubMed ID: 24372462
[TBL] [Abstract][Full Text] [Related]
55. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
Levis S; Theodore G
J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
[TBL] [Abstract][Full Text] [Related]
56. Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases.
Olsen KR; Hansen C; Abrahamsen B
Osteoporos Int; 2013 Oct; 24(10):2639-47. PubMed ID: 23604250
[TBL] [Abstract][Full Text] [Related]
57. Fracture risk and healthcare resource utilization and costs among osteoporosis patients with type 2 diabetes mellitus and without diabetes mellitus in Japan: retrospective analysis of a hospital claims database.
Sato M; Ye W; Sugihara T; Isaka Y
BMC Musculoskelet Disord; 2016 Nov; 17(1):489. PubMed ID: 27887655
[TBL] [Abstract][Full Text] [Related]
58. Comparative effectiveness of osteoporosis drugs in preventing secondary nonvertebral fractures in Taiwanese women.
Lin TC; Yang CY; Yang YH; Lin SJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):4717-26. PubMed ID: 24081731
[TBL] [Abstract][Full Text] [Related]
59. Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.
Wilk A; Sajjan S; Modi A; Fan CP; Mavros P
Osteoporos Int; 2014 Dec; 25(12):2777-86. PubMed ID: 25112720
[TBL] [Abstract][Full Text] [Related]
60. Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.
Zhao Y; Johnston SS; Smith DM; McMorrow D; Krohn K; Krege J
Osteoporos Int; 2013 Sep; 24(9):2525-33. PubMed ID: 23529293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]